Suchergebnisse - "Gogishvili, Miranda"

PubPharm (8)

1

First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1) : 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2023

von Özgüroğlu, M. | Kilickap, S. | Sezer, A. | +21

ErratumIn: Lancet Oncol. 2023 Oct;24(10):e405. - PMID 37797644

2

Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer : Patient-reported outcomes from phase 3 EMPOWER-Lung 3

enthalten in: Cancer | 2023

von Makharadze, T. | Quek, R. | Melkadze, T. | +16

3

Response to Letter to the Editor

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Makharadze, T. | Gogishvili, M. | Baramidze, A. | +7

4

Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC : 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Makharadze, T. | Gogishvili, M. | Melkadze, T. | +17

CommentIn: J Thorac Oncol. 2023 Jul;18(7):e72-e73. - PMID 37348996

5

Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50% : The EMPOWER-Lung 1 study

enthalten in: Cancer | 2023

von Gümüş, M. | Chen, C. | Ivanescu, C. | +17

ErratumIn: Cancer. 2024 Feb 23;:. - PMID 38396349

6

Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50% : The EMPOWER‐Lung 1 study

enthalten in: Cancer | 2023

von Gümüş, M. | Chen, C. | Ivanescu, C. | +17

7

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer : a randomized, controlled, double-blind phase 3 trial

enthalten in: Nature medicine | 2022

von Gogishvili, M. | Melkadze, T. | Makharadze, T. | +23

8

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50% : a multicentre, open-label, global, phase 3, randomised, controlled trial

enthalten in: Lancet (London, England) | 2021

von Sezer, A. | Kilickap, S. | Gümüş, M. | +24

CommentIn: Lancet. 2021 Feb 13;397(10274):557-559. - PMID 33581807

1
[1]